FOXA1突变通过改变染色质状态影响乳腺癌的治疗反应。

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-05-05 eCollection Date: 2021-01-01 DOI:10.1080/23723556.2021.1891831

Amaia Arruabarrena-Aristorena, Eneda Toska

{"title":"FOXA1突变通过改变染色质状态影响乳腺癌的治疗反应。","authors":"Amaia Arruabarrena-Aristorena, Eneda Toska","doi":"10.1080/23723556.2021.1891831","DOIUrl":null,"url":null,"abstract":"ABSTRACT Forkhead box protein A1 (FOXA1) is a pioneer transcription factor that contributes to chromatin opening to allow binding of estrogen receptor (ER) in ER+ breast cancer. Mutations in FOXA1 are recurrent in breast cancer but the functional consequences of these mutations remain unknown. We identified that FOXA1 mutations are associated with worse outcomes to endocrine therapy by inducing alternative chromatin profiles and gene activity in breast cancer.","PeriodicalId":37292,"journal":{"name":"Molecular and Cellular Oncology","volume":"8 3","pages":"1891831"},"PeriodicalIF":2.6000,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23723556.2021.1891831","citationCount":"0","resultStr":"{\"title\":\"<i>FOXA1</i> mutations influence the therapeutic response of breast cancer by altering chromatin state.\",\"authors\":\"Amaia Arruabarrena-Aristorena, Eneda Toska\",\"doi\":\"10.1080/23723556.2021.1891831\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Forkhead box protein A1 (FOXA1) is a pioneer transcription factor that contributes to chromatin opening to allow binding of estrogen receptor (ER) in ER+ breast cancer. Mutations in FOXA1 are recurrent in breast cancer but the functional consequences of these mutations remain unknown. We identified that FOXA1 mutations are associated with worse outcomes to endocrine therapy by inducing alternative chromatin profiles and gene activity in breast cancer.\",\"PeriodicalId\":37292,\"journal\":{\"name\":\"Molecular and Cellular Oncology\",\"volume\":\"8 3\",\"pages\":\"1891831\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2021-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23723556.2021.1891831\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular and Cellular Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23723556.2021.1891831\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23723556.2021.1891831","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

叉头盒蛋白A1 (FOXA1)是一种先锋转录因子，在ER+乳腺癌中促进染色质开放，允许雌激素受体(ER)结合。FOXA1突变在乳腺癌中会复发，但这些突变的功能后果尚不清楚。我们发现FOXA1突变通过诱导乳腺癌中不同的染色质谱和基因活性与内分泌治疗的不良结果相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

FOXA1 mutations influence the therapeutic response of breast cancer by altering chromatin state.

ABSTRACT Forkhead box protein A1 (FOXA1) is a pioneer transcription factor that contributes to chromatin opening to allow binding of estrogen receptor (ER) in ER+ breast cancer. Mutations in FOXA1 are recurrent in breast cancer but the functional consequences of these mutations remain unknown. We identified that FOXA1 mutations are associated with worse outcomes to endocrine therapy by inducing alternative chromatin profiles and gene activity in breast cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.